Acurx Pharmaceuticals
ACXP
22 hedge funds and large institutions have $2.41M invested in Acurx Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 4 closing their positions.
0.01% more ownership
Funds ownership: 0.38% → 0.39% (+0.01%)
11% less capital invested
Capital invested by funds: $2.71M → $2.41M (-$303K)
12% less funds holding
Funds holding: 25 → 22 (-3)
17% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 6
32% less call options, than puts
Call options by funds: $17K | Put options by funds: $25K
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$79.7K |
| 2 |
SG
StoneX Group
New York
|
+$37.7K |
| 3 |
PFS
Prospect Financial Services
Melville,
New York
|
+$35.9K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$34.9K |
| 5 |
BlackRock
New York
|
+$2.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
-$23K |
| 2 |
LPL Financial
San Diego,
California
|
-$19K |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$10.7K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$4.4K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$3.73K |
ACXP Hedge Fund Activity: Q3 2024 in Review
22 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Acurx Pharmaceuticals (ACXP) for Q3 2024, worth a combined $2.41M — down 11% from $2.71M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of ACXP and 1 opened new positions — a net loss of 3 holders — while 6 trimmed existing stakes and 5 added.
The largest buyer was Vanguard Group, adding an estimated $79.7K. The largest seller was Cambridge Investment Research Advisors, exiting entirely with an estimated $23K sold.
- 22 institutional investors held Acurx Pharmaceuticals (ACXP) as of Q3 2024, down from 25 in Q2 2024.
- Funds reported $2.41M of Acurx Pharmaceuticals stock for Q3 2024, down 11% quarter-over-quarter.
- 1 fund opened new Acurx Pharmaceuticals positions in Q3 2024 and 4 closed out, a net change of -3 holders.
- The largest Acurx Pharmaceuticals buyer in Q3 2024 was Vanguard Group, an estimated $79.7K added.
- The largest Acurx Pharmaceuticals seller in Q3 2024 was Cambridge Investment Research Advisors, an estimated $23K sold.
Based on aggregated 13F filings for Q3 2024.